Oxurion NV – Data from a Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for DME presented at 2019 FLORetina Meeting

Ads

You May Also Like

Coherus BioSciences Reports First Quarter 2016 Financial and Operating Results

CHS-1420 (adalimumab biosimilar) Formulation Patents to Issue in MayCompleted Private Convertible Financing of $100 ...